We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
101
DELISTED
Akero Therapeutics
AKRO
$3.43M 0.01%
118,378
– –
LEGN icon
102
Legend Biotech
LEGN
$3.64B
$3.35M 0.01%
115,626
– –
LOGC
103
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$3.29M 0.01%
451,478
– –
TARA icon
104
Protara Therapeutics
TARA
$214M
$3.14M 0.01%
199,671
– –
XLRN
105
DELISTED
Acceleron Pharma
XLRN
$3.04M 0.01%
22,430
– –
CNST
106
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.68M 0.01%
114,735
– –
ACGN
107
DELISTED
Aceragen Inc
ACGN
$2.66M 0.01%
120,543
-150,833
-56% -$11.3M
AUTL
108
Autolus Therapeutics
AUTL
$378M
$2.65M 0.01%
461,726
-320,457
-41% -$2.37M
CHMA
109
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.32M 0.01%
742,133
– –
VKTX icon
110
Viking Therapeutics
VKTX
$3.82B
$2.3M 0.01%
363,980
– –
INZY
111
DELISTED
Inozyme Pharma
INZY
$2.12M 0.01%
106,999
– –
MTEM
112
DELISTED
Molecular Templates, Inc.
MTEM
$1.69M 0.01%
8,922
– –
AFMD
113
DELISTED
Affimed
AFMD
$1.3M 0.01%
16,461
– –
OYST
114
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.12M ﹤0.01%
61,424
– –
CYPH
115
Cypherpunk Technologies Inc
CYPH
$62.8M
$1.06M ﹤0.01%
55,971
– –
BLCM
116
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$937K ﹤0.01%
249,123
– –
LKFT
117
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$862K ﹤0.01%
11,180
– –
KZR
118
DELISTED
Kezar Life Sciences
KZR
$832K ﹤0.01%
13,968
– –
ADMS
119
DELISTED
Adamas Pharmaceuticals
ADMS
$710K ﹤0.01%
147,996
– –
GLMD icon
120
Galmed Pharmaceuticals
GLMD
$4.41M
$634K ﹤0.01%
1,027
– –
IFRX icon
121
InflaRx
IFRX
$243M
$538K ﹤0.01%
138,040
-718,188
-84% -$3.68M
KRRO icon
122
Korro Bio
KRRO
$144M
$528K ﹤0.01%
1,111
-16,019
-94% -$31.1M
GNFT
123
DELISTED
Genfit
GNFT
$68K ﹤0.01%
14,720
– –
ADPT icon
124
Adaptive Biotechnologies
ADPT
$3.5B
– –
-379,682
Closed -$22.5M
GOSS icon
125
Gossamer Bio
GOSS
$92.8M
– –
-480,729
Closed -$4.65M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.